Matches in SemOpenAlex for { <https://semopenalex.org/work/W2542382128> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2542382128 endingPage "674" @default.
- W2542382128 startingPage "670" @default.
- W2542382128 abstract "Squamous cell carcinoma (SCC) is a common pathological type of non-small cell lung cancer, and advanced lung SCC is incurable. Chemotherapy combined with anti-angiogenesis agents can prolong the patients' survival time. The aim of the study was to analyze the efficacy and safety of recombinant human endostatin (Endostar) in treating advanced lung SCC.We retrospectively analyzed the short-term efficacy and toxicity of recombinant human endostatin combined with traditional chemotherapy regimens in treating 15 advanced lung squamous cell carcinoma patients in Department of Medical Oncology retrospectively, Cancer Hospital, Chinese Academy of Medical Sciences from November 2011 to May 2015. Treatment-related survival was also analyzed.Among the evaluble 14 patients, the best overall response was partial response in 5 patients (35.7%), stable disease in 7 patients (50.0%), and progressive disease in 2 patients (14.3%). The objective response rate (ORR) was 35.7%, and disease control rate (DCR) was 85.7%. The median progression-free survival (PFS) was 9.3 months. The main grade 3 toxicity was neutropenia (2/15, 13.3%) and vomitting (1/15, 6.7%).Chemotherapy combined with recombinant human endostatin enabled good objective response in advanced SCC patients and had well security.背景与目的 肺鳞癌是非小细胞肺癌常见的病理类型，晚期肺鳞癌是一种无法治愈的恶性肿瘤。抗血管生成药物与传统化疗联合能够为患者带来生存改善。本研究分析了重组人血管内皮抑制素（恩度）联合化疗治疗晚期肺鳞癌的疗效及安全性。方法 回顾性分析中国医学科学院肿瘤医院内科2011年11月-2015年5月采用人血管内皮抑制素联合传统化疗方案治疗的15例晚期肺鳞癌患者的近期疗效、毒副反应及无进展生存时间。结果 14例可评估患者中疗效评价最佳即为部分缓解5例（35.7%）、疾病稳定7例（50.0%）、疾病进展2例（14.3%），客观缓解率为35.7%，疾病控制率为85.7%，中位无进展生存为9.3个月。全组患者治疗耐受良好，3度不良反应表现为中性粒细胞减少（2/15, 13.3%）和呕吐（1/15, 6.7%），其余不良事件均为1度/2度。结论 重组人血管内皮抑制素联合化疗治疗晚期肺鳞癌可取得较好的客观疗效并且安全性良好。." @default.
- W2542382128 created "2016-11-04" @default.
- W2542382128 creator A5003642180 @default.
- W2542382128 creator A5030376299 @default.
- W2542382128 creator A5045176687 @default.
- W2542382128 creator A5048001385 @default.
- W2542382128 creator A5068920157 @default.
- W2542382128 date "2016-10-20" @default.
- W2542382128 modified "2023-10-17" @default.
- W2542382128 title "[Recombinant Human Endostatin in the Treatment of Advanced Lung Squamous Cell Carcinoma]." @default.
- W2542382128 cites W1505512293 @default.
- W2542382128 cites W1775905963 @default.
- W2542382128 cites W1978139448 @default.
- W2542382128 cites W1980448975 @default.
- W2542382128 cites W1982246723 @default.
- W2542382128 cites W2016641845 @default.
- W2542382128 cites W2081732184 @default.
- W2542382128 cites W2100785570 @default.
- W2542382128 cites W2101569260 @default.
- W2542382128 cites W2102056525 @default.
- W2542382128 cites W2108215699 @default.
- W2542382128 cites W2140980839 @default.
- W2542382128 cites W2159370421 @default.
- W2542382128 cites W2170552969 @default.
- W2542382128 cites W2170744484 @default.
- W2542382128 cites W2354449954 @default.
- W2542382128 cites W2413151750 @default.
- W2542382128 doi "https://doi.org/10.3779/j.issn.1009-3419.2016.10.06" @default.
- W2542382128 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5973421" @default.
- W2542382128 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27760596" @default.
- W2542382128 hasPublicationYear "2016" @default.
- W2542382128 type Work @default.
- W2542382128 sameAs 2542382128 @default.
- W2542382128 citedByCount "2" @default.
- W2542382128 countsByYear W25423821282017 @default.
- W2542382128 countsByYear W25423821282022 @default.
- W2542382128 crossrefType "journal-article" @default.
- W2542382128 hasAuthorship W2542382128A5003642180 @default.
- W2542382128 hasAuthorship W2542382128A5030376299 @default.
- W2542382128 hasAuthorship W2542382128A5045176687 @default.
- W2542382128 hasAuthorship W2542382128A5048001385 @default.
- W2542382128 hasAuthorship W2542382128A5068920157 @default.
- W2542382128 hasConcept C121608353 @default.
- W2542382128 hasConcept C126322002 @default.
- W2542382128 hasConcept C143998085 @default.
- W2542382128 hasConcept C2776256026 @default.
- W2542382128 hasConcept C2776694085 @default.
- W2542382128 hasConcept C2777063308 @default.
- W2542382128 hasConcept C2778822529 @default.
- W2542382128 hasConcept C29730261 @default.
- W2542382128 hasConcept C71924100 @default.
- W2542382128 hasConcept C90924648 @default.
- W2542382128 hasConceptScore W2542382128C121608353 @default.
- W2542382128 hasConceptScore W2542382128C126322002 @default.
- W2542382128 hasConceptScore W2542382128C143998085 @default.
- W2542382128 hasConceptScore W2542382128C2776256026 @default.
- W2542382128 hasConceptScore W2542382128C2776694085 @default.
- W2542382128 hasConceptScore W2542382128C2777063308 @default.
- W2542382128 hasConceptScore W2542382128C2778822529 @default.
- W2542382128 hasConceptScore W2542382128C29730261 @default.
- W2542382128 hasConceptScore W2542382128C71924100 @default.
- W2542382128 hasConceptScore W2542382128C90924648 @default.
- W2542382128 hasIssue "10" @default.
- W2542382128 hasLocation W25423821281 @default.
- W2542382128 hasOpenAccess W2542382128 @default.
- W2542382128 hasPrimaryLocation W25423821281 @default.
- W2542382128 hasRelatedWork W2045806517 @default.
- W2542382128 hasRelatedWork W2070962078 @default.
- W2542382128 hasRelatedWork W2083033314 @default.
- W2542382128 hasRelatedWork W2124411053 @default.
- W2542382128 hasRelatedWork W219088554 @default.
- W2542382128 hasRelatedWork W2402993451 @default.
- W2542382128 hasRelatedWork W2413020017 @default.
- W2542382128 hasRelatedWork W2425367433 @default.
- W2542382128 hasRelatedWork W3032349186 @default.
- W2542382128 hasRelatedWork W3189911105 @default.
- W2542382128 hasVolume "19" @default.
- W2542382128 isParatext "false" @default.
- W2542382128 isRetracted "false" @default.
- W2542382128 magId "2542382128" @default.
- W2542382128 workType "article" @default.